Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017 - MarketsandMarkets

Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017

Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017 - MarketsandMarkets
Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017
Published Mar 28, 2013
148 pages — Published Mar 28, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:



Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications.

The global market (2012-2017) report analyses the market by technology, products, applications, and geography. It also includes recent technology trends, patents, and funding analysis. In addition, it also covers factors driving and restraining the growth of the market and market scenario in the U.S., Europe, Asia, and Rest of the World (RoW).

The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. However, development costs, stringent regulatory issues, and risk of failure of the drug in the testing phase restraints the growth of the market. Further, the availability of generics and patent infringements is posing a threat to the market.

The global market is expected to grow at a CAGR of 10.9%; this growth is majorly fuelled by monoclonal antibodies, which is the fastest growing segment in therapeutics. The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market. Diagnostics is another segment in focus; monoclonal antibodies are being used extensively in diagnostics and in assays for research.

The report also profiles leading participants of the industry with their recent developments and other strategic industry activities. These include Genentech (U.S.), Amgen (U.S.), Roche (Switzerland), Eli Lilly (U.S.), Novartis (Switzerland), GlaxoSmithKline (U.K.), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax (U.S.), Biogen Idec, (U.S.), Medimmune (U.S.) Affimed (Germany), and Obodies (New Zealand).

Scope of the Report

This technical report categorizes the market for protein engineering by geography, applications, products, and technology, forecasting the market revenue by analyzing current and future trends in therapeutics and diagnostics.These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global Protein engineering, by Technology

Sequence modification
Glycosylation
Pegylation
Display technologies
Humanization technology
Hybrid technology
Transgenic mice

Global Protein engineering, by Product

mAb
Insulin
Others
EPO
Diagnostics
Research

Ge

  
Source:
Document ID
BT 1358
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title
Table Of Content

1 Introduction (Slide No. 18 - 23)
1.1 Key Take- Aways
1.2 Assumptions
1.3 Report Scope
1.4 Research Methodology
1.5 Key Data Points From Primary And Secondary Sources

2 Executive Summary (Slide No. 24 - 27)

3 Protein Engineering Technologies - Landscape Analysis (Slide No. 28 - 45)
3.1 Technology - Introduction
3.2 Technology - Evolution
3.3 Market Segmentation
3.4 Protein And Antibody Engineering Technologies - Overview
3.4.1 Sequence Modification
3.4.2 Glycosylation
3.4.3 Pegylation
3.4.4 Display Technologies
3.4.5 Humanization Technology
3.4.6 Hybrid Technology
3.4.7 Production Systems
3.4.8 Mapping Of Protein Production Systems
3.4.9 Emerging Production Systems
3.5 Protein Engineering - Technology Value Chain Analysis

4 Applications (Slide No. 46 - 54)
4.1 Therapeutic Development - Overview
4.1.1 Insulin Analogs
4.1.2 Monoclonal Antibodies
4.1.3 Therapeutic Development - Erythropoietin & Others
4.2 Diagnostics
4.3 Research - Meganuclease Engineering / ZFP & TALENS Engineering

5 Market Landscape Analysis (Slide No. 55 - 92)
5.1 Global Protein Engineering Market Forecast
5.1.1 Introduction
5.1.2 Global Market Forecast, By Geography
5.1.3 Global Market Forecast, By Product
5.1.4 Global Market Forecast, By Application
5.1.5 Global Market Forecast, By Technology
5.2 Market Dynamics - Overview
5.2.1 Drivers - Description
5.2.2 Drivers' Impact - Timeline
5.2.3 Restraints - Description
5.2.4 Restraints Impact - Timeline
5.2.5 Opportunities - Description
5.2.6 Threats - Description
5.2.7 Pestle Analysis
5.3 Market Segmentation, By Product
5.3.1 Insulin Analogs
5.3.1.1 Insulin Analog Market
5.3.1.2 Insulin Analog Market, By Geography
5.3.1.3 Market Share Analysis
5.3.2 Modified EPO
5.3.2.1 Modified EPO Market
5.3.2.2 Modified EPO Market, By Geography
5.3.3 Monoclonal Antibodies (MAB)
5.3.3.1 Monoclonal Antibodies Market
5.3.3.2 Monoclonal Antibodies Market, By Geography
5.3.3.3 Monoclonal Antibodies Market, By Application
5.3.3.4 Major Products In The Market
5.4 Other Proteins
5.4.1 Other Proteins Market
5.4.2 Other Proteins Market, By Geography
5.4.3 Diagnostic Proteins, By Geography

6 Geographic Analysis (Slide No. 93 - 100)
6.1 North America
6.2 Europe
6.3 Asia
6.4 Row

7 Technology And Product Portfolio (Slide No. 101 - 105)
7.1 Proprietary Technology Platforms
7.2 Product Pipeline Analysis Of Key Players

8 Competitive Landscape (Slide No. 106 - 111)
8.1 Introduction
8.2 Porter's Five Force Analysis
8.3 Mergers & Acquisitions, 2009 - 2012
8.4 Partnerships & Collaborations, 2012 - 2013
8.5 New Product Launch, 2010 - 2012

9 Analyst Insights And Recommendation (Slide No. 112 - 114)
9.1 Strategic Recommendations

10 Company Profiles (Slide No. 115 - 146)
10.1 Genentech, Inc.
10.2 Amgen, Inc.
10.3 Biogen Idec,

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017" Mar 28, 2013. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/Protein-Engineering-Market-Products-Monoclonal-Antibody-Insulin-Analog-Modified-EPO-Technology-Sequential-Modification-Glycosylation-PEGylation-and-Applications-Therapeutics-Diagnostics-Research-Global-Forecast-to-2017-2144-84>
  
APA:
MarketsandMarkets. (2013). Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017 Mar 28, 2013. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/Protein-Engineering-Market-Products-Monoclonal-Antibody-Insulin-Analog-Modified-EPO-Technology-Sequential-Modification-Glycosylation-PEGylation-and-Applications-Therapeutics-Diagnostics-Research-Global-Forecast-to-2017-2144-84>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.